Reporting on Adverse Clinical Events, 2018

DOI: 10.1177/0069477018768178

Keywords: Anti–Tumor Necrotizing Factor Agents (81),Bisoprolol (78),Clomiphene Citrate (77),Compounded Drug Products (88),Dietary Supplement (80),Enoxaparin (76),Enzalutamide (87),Erlotinib (86),Fluphenazine Decanoate (75),Gentamicin (84),Glucocorticoids (83),Heparin (76),Idarucizumab (79),Lenalidomide (74),Methadone (85),Oxcarbazepine (82),Warfarin (87)

Full-Text